Research has shown that B2M was high expression in prostate cancer cells and increased B2M was related to distance metastasis [37], and increased serum levels of B2M and FLT3-L in patients with multiple myeloma may be associated with increased angiogenesis and myelosuppression [38]. Here, B2M is linked to prostate carcinoma.